The company, founded in New Zealand in 2019, is led by Irish-born CEO and co-founder Dr Brendan Darby with offices in Dublin and Wellington (New Zealand).
The investment from Enterprise Ireland will be used to fund the expansion of Marama Labs’ Irish operations, opening a commercially-focused applications lab in North Dublin and hiring a life-sciences applications team to support its customers in the Northern Hemisphere.
Marama Labs develops novel spectroscopy technology that can rapidly analyse the chemistry of highly complex high-value liquids in industries such as life sciences and fermentation. Its CloudSpec product is able to quantify crucial quality information about new classes of therapeutics, called nanomedicines, in seconds, compared to hours it takes with existing technologies.
Marama Labs is working with some of the world’s leading therapeutic manufacturers to speed up their drug discovery and manufacturing workflows, with the life sciences product due to launch on the market in 2025.
Tom Kelly, Divisional Manager, Industrial & Life Sciences at Enterprise Ireland said: “Congratulations to the team at Marama Labs on its recent investment wins. Enterprise Ireland’s HPSU investment in this highly innovative company will support its exploration into the rapidly growing life-sciences market and the expansion of its operations in Ireland.”
